[
  {
    "ts": null,
    "headline": "Galderma Bets on Skin Drug to Turn Around Pharma Business",
    "summary": "Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.",
    "url": "https://finnhub.io/api/news?id=7d506eac6c36635577ff1987f81204851e80c7f95849e17679e8a0599da2366c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732898160,
      "headline": "Galderma Bets on Skin Drug to Turn Around Pharma Business",
      "id": 131710886,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.",
      "url": "https://finnhub.io/api/news?id=7d506eac6c36635577ff1987f81204851e80c7f95849e17679e8a0599da2366c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=12bb1fe8556925a3e1d3b69147f321b10472aca7ecc095e5b898b24bdd54936b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732898040,
      "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "id": 131775423,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=12bb1fe8556925a3e1d3b69147f321b10472aca7ecc095e5b898b24bdd54936b"
    }
  },
  {
    "ts": null,
    "headline": "Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?",
    "summary": "AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=a2445c379ba7393a1d8f040ef6de90089c51c1dba0fa01a3bffc208de044219b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732897902,
      "headline": "Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?",
      "id": 131714562,
      "image": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=a2445c379ba7393a1d8f040ef6de90089c51c1dba0fa01a3bffc208de044219b"
    }
  },
  {
    "ts": null,
    "headline": "With 73% ownership in AbbVie Inc. (NYSE:ABBV), institutional investors have a lot riding on the business",
    "summary": "Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...",
    "url": "https://finnhub.io/api/news?id=f6547b50f155f27435fca09b75c3c0d5c581666f5e262345cbb7893e402ab5fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732878034,
      "headline": "With 73% ownership in AbbVie Inc. (NYSE:ABBV), institutional investors have a lot riding on the business",
      "id": 131704807,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/b1235bf6d18ebc2cd7323427468d0693",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...",
      "url": "https://finnhub.io/api/news?id=f6547b50f155f27435fca09b75c3c0d5c581666f5e262345cbb7893e402ab5fd"
    }
  },
  {
    "ts": null,
    "headline": "Forget Big Tech - I'll Take Dividend Stalwarts Any Day",
    "summary": "Discover why dividend stocks in VYM and SCHD ETFs offer a safer alternative to tech investments, with strong cash flow, low risks, and reliable growth. Read what investors need to know.",
    "url": "https://finnhub.io/api/news?id=a8a735e7b1273f4a2c8451dcb50ebf7ae4ff50766d6e4bde3cadfe36b59eea7f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732865400,
      "headline": "Forget Big Tech - I'll Take Dividend Stalwarts Any Day",
      "id": 131705151,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184095763/image_184095763.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why dividend stocks in VYM and SCHD ETFs offer a safer alternative to tech investments, with strong cash flow, low risks, and reliable growth. Read what investors need to know.",
      "url": "https://finnhub.io/api/news?id=a8a735e7b1273f4a2c8451dcb50ebf7ae4ff50766d6e4bde3cadfe36b59eea7f"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
    "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732841400,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
      "id": 131700113,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1633433467/image_1633433467.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8"
    }
  }
]